Why Regencell Bioscience Holdings Limited’s (RGC) Stock Is Up 5.96%
As of Friday, July 17, Regencell Bioscience Holdings Limited’s RGC share price has surged by 5.96%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Stock Evaluator: Regencell Bioscience Holdings Limited (RGC)
Regencell Bioscience Holdings Limited RGC
$5.28
-0.13
-2.40%
August 10, 2026 4:00:00 PM
EST
Volume: 203,505
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Commentary & Analysis
Why Regencell Bioscience Holdings Limited’s (RGC) Stock Is Down 5.56%
As of Thursday, July 16, Regencell Bioscience Holdings Limited’s RGC share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Regencell Bioscience Holdings Limited’s (RGC) Stock Is Down 5.13%
As of Wednesday, July 15, Regencell Bioscience Holdings Limited’s RGC share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Regencell Bioscience Holdings Limited’s (RGC) Stock Is Up 5.84%
As of Tuesday, July 14, Regencell Bioscience Holdings Limited’s RGC share price has surged by 5.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Regencell Bioscience Holdings Limited’s (RGC) Stock Is Up 11.62%
As of Tuesday, July 14, Regencell Bioscience Holdings Limited’s RGC share price has surged by 11.62%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | RGC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,675.6 | $620.4 | 57% |
|
| Shares Out (Mil) | 494.5 | 43.1 | 88% |
|
| Institutional Ownership | 0.2% | 84.4% | 1% |
|
| Float (Mil) | 56.4 | 47.1 | 50% |
|
| Beta | 1.64 | 0.64 | 86% |
|
| Avg Daily Volume (000s) | 210 | 304 | 45% |
|
| Price Change (52-week) |
(57.1%) | 67.3% | 12% |
|
| Growth | RGC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (35.1%) | (1.4%) | 11% |
|
| EPS (5yr) | (28.5%) | 14.9% | 9 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 0.0% | (14.9%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RGC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $275 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 32% |
|
| EPS (TTM) | ($0.014) | ($0.600) | 39% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($6) | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | $10,596 | $466 | 75% |
|
| Valuation | RGC | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.92 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RGC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.8% | na |
|
| Net Margin | na | 0.2% | na |
|
| ROA | (134.4%) | (21.5%) | 4% |
|
| ROE | (177.7%) | (16.0%) | 5% |
|
| Liabilities to Assets | 59.5% | 34.8% | 53% |
|
| F-Score | 2 | 3 | 7% |
|
Regencell Bioscience Holdings Limited did not pass any screens on 8/7/2026.
